Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002878 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002878 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00002878, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective than combination chemotherapy alone in treating patients with relapsed or refractory multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG doxorubicin hydrochloride
- DRUG vincristine sulfate
- DRUG valspodar
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002878
The ClinicalTrials.gov registry entry for NCT00002878 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00002878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002878 about?
NCT00002878 is a clinical study titled "Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet kn...
What is the current status of trial NCT00002878?
This trial is currently completed. It is a Phase 3 study. The study started on 1997-06-30.
What interventions are being tested in trial NCT00002878?
The interventions under investigation include: dexamethasone (DRUG), doxorubicin hydrochloride (DRUG), vincristine sulfate (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00002878?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.